Invivyd (IVVD) Profit After Tax (2021 - 2026)
Invivyd's (IVVD) quarterly Profit After Tax came in at -$44.4 million in Q2 2026, down 202.28% on a YoY basis from $43.4 million in Q2 2025, and down 301.02% quarter-over-quarter from -$11.1 million in Q4 2025.
Analysis
Invivyd (IVVD) Profit After Tax (2021 - 2026) Analysis & Trends
Invivyd (IVVD) has reported Profit After Tax for 6 consecutive years, with -$44.4 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Profit After Tax fell 202.28% year-over-year to -$44.4 million; the trailing twelve-month figure through Jun 2026 stood at -$80.6 million (up 26.81% YoY), and the FY2025 full-year result was -$52.5 million, up 69.09% from the prior year.
- Profit After Tax retreated to -$44.4 million in Q2 2026 per IVVD's latest filing, from -$11.1 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$10.5 million in Q3 2025 and bottomed at -$100.7 million in Q1 2022.
- Historically, Profit After Tax has averaged -$41.6 million across 5 years, with a median of -$44.4 million in 2026.
- The sharpest annual moves came in 2025 and 2026: Profit After Tax soared 82.76% in 2025, then plunged 202.28% in 2026.
- Over 5 years, Profit After Tax stood at -$44.8 million in 2022, then sank by 64.27% to -$73.7 million in 2023, then surged by 74.97% to -$18.4 million in 2024, then surged by 39.96% to -$11.1 million in 2025, then sank by 301.02% to -$44.4 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$44.4 million, -$11.1 million, and -$10.5 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 472.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | -44.39 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -44.39 Mn |
| Dec 31, 2025 | -11.07 Mn |
| Sep 30, 2025 | -10.47 Mn |
| Jun 30, 2025 | -14.69 Mn |
| Mar 31, 2025 | -16.29 Mn |
| Dec 31, 2024 | -18.44 Mn |
| Sep 30, 2024 | -60.75 Mn |
| Jun 30, 2024 | -47.25 Mn |
| Mar 31, 2024 | -43.50 Mn |
| Dec 31, 2023 | -73.65 Mn |
| Sep 30, 2023 | -39.44 Mn |
| Jun 30, 2023 | -50.23 Mn |
| Mar 31, 2023 | -35.32 Mn |
| Dec 31, 2022 | -44.84 Mn |
| Sep 30, 2022 | -45.09 Mn |
| Jun 30, 2022 | -50.99 Mn |
| Mar 31, 2022 | -100.67 Mn |
| Dec 31, 2021 | -83.04 Mn |
| Sep 30, 2021 | -60.38 Mn |
| Jun 30, 2021 | -44.67 Mn |